For the quarter ending 2026-03-31, MBRX has $23,363K in assets. $8,180K in debts. $10,317K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 10,317 | 8,878 | 6,703 | 7,557 |
| Prepaid expenses and other current assets | 644 | 808 | 1,182 | 1,519 |
| Total current assets | 10,961 | 9,686 | 7,885 | 9,076 |
| Intangible assets | 11,148 | 11,148 | 11,148 | 11,148 |
| Other non-current assets | 900 | 900 | 900 | 900 |
| Operating lease right-of-use asset | 284 | 314 | 343 | 370 |
| Furniture and equipment, net | 70 | 78 | 77 | 99 |
| Total assets | 23,363 | 22,126 | 20,353 | 21,593 |
| Accounts payable | 4,574 | 3,508 | 2,116 | 3,721 |
| Accrued expenses and other current liabilities | 3,388 | 3,346 | 3,566 | 4,192 |
| Total current liabilities | 7,962 | 6,854 | 5,682 | 7,913 |
| Operating lease liability - long-term, net of current portion | 185 | 222 | 258 | 292 |
| Warrant liability | 33 | 44 | 41,333 | 20,553 |
| Total liabilities | 8,180 | 7,120 | 47,273 | 28,758 |
| Common stock, 0.001 par value 500,000,000 shares authorized 5,336,350 and 3,199,228 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 5 | 3 | 49 | 30 |
| Accumulated other comprehensive loss | - | - | -44 | -38 |
| Additional paid-in capital | 234,079 | 220,997 | 194,631 | 160,286 |
| Accumulated other comprehensive income (loss) | -52 | 10 | - | - |
| Accumulated deficit | -218,849 | -206,004 | -221,556 | -167,443 |
| Total stockholders equity | 15,183 | 15,006 | -26,920 | -7,165 |
| Total liabilities and stockholders equity | 23,363 | 22,126 | 20,353 | 21,593 |
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)